BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the dossier 
The company SBL Vaccin AB submitted on 1 March 2002 an application for Marketing Authorisation 
to the European Agency for the Evaluation of Medicinal Products (EMEA) for Dukoral, in accordance 
with the centralised procedure falling within the scope of Part A of the Annex to Council Regulation 
No (EEC) 2309/93 of 22 July 1993. 
The Rapporteur and Co-Rapporteur appointed by the CPMP were: 
Rapporteur: 
Per Nilsson 
Co-Rapporteur:  Manfred Haase 
Licensing status: 
Dukoral  has  been  granted  national  Marketing  Authorisations  in  Sweden  in  1991  and  in  Norway  in 
1997. Additionally, Dukoral has been approved in 12 countries such as Peru and Guatemala (1996), 
Argentina, El Salvador, Honduras and Nicaragua (1997), Madagaskar (1999), Estonia (2000), Mexico, 
Kenya,  Mauritius  and  the  Philippines  (2001).  An  application  is  pending  in  11  countries  including 
among others Switzerland, Canada, New Zealand, Thailand and South Africa. Since 2001 Dukoral is 
recommended by the WHO for immunisation against cholera in endemic areas and is the only cholera 
vaccine included in the list of “United Nations Prequalified Vaccines” for the prevention of cholera in 
endemic regions.  
2. 
Steps taken for the assessment of the product 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
The procedure started on 26 March 2002. 
The Rapporteur's first Assessment Report was circulated to all CPMP members on 4 June 2002. 
The  Co-Rapporteur's  first  Assessment  Report was circulated to  all CPMP members on 7 June 
2002. 
During  the  meeting  on  23 –  25  July  2002  the  CPMP  agreed  on  the  consolidated  List  of 
Questions to be sent to the applicant. The final consolidated List of Questions was sent to the 
applicant on 25 July 2002. 
The  company  submitted  the  responses  to  the  CPMP  consolidated  List  of  Questions  on  
16 January 2003. 
The joint response Assessment Report on the company’s responses to the List of Questions was 
circulated to all CPMP members on 19 February 2003. 
During the meeting on 18 – 20 March 2003 the CPMP adopted the List of Outstanding Issues. 
The  company  submitted  the  written  responses  to  the  List  of  Outstanding  issues  on 
30 May 2003. 
The joint response Assessment Report on the company’s responses to  the  List of Outstanding 
Issues was circulated to all CPMP members on 13 June 2003. 
During  the  CPMP  meeting  on  24  –  26  June  2003  outstanding  issues  were  addressed  by  the 
applicant during a hearing before the CPMP. 
A Rapporteur’s pre-opinion report was circulated to all CPMP members on 16 July 2003. 
During the meeting on 22-24 July 2003 the CPMP, in the light of the overall data submitted and 
the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a 
Marketing Authorisation to Dukoral on 24 July 2003. 
The  European  Commission  returned  the  initial  CPMP  Opinion  of  July  2003  to  the  EMEA, 
requesting to reconsider this application according to a different legal basis. 
1/2 
EMEA 2005 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
• 
During  the  meeting  on  24-  26  February  2004  the  CPMP,  in  the  light  of  the  overall  data  and 
justification  submitted  and  the  scientific  discussion  within  the  Committee,  issued  a  revised 
positive Opinion for granting a Marketing Authorisation for Dukoral. 
2/2 
EMEA 2005 
 
 
 
 
 
 
 
